Breaking News Instant updates and real-time market news.

ALXN

Alexion

$146.46

2.39 (1.66%)

18:01
09/13/17
09/13
18:01
09/13/17
18:01

Alexion: Soliris study results show sustained treatment benefits

Alexion Pharmaceuticals announced results from an interim analysis of an ongoing Phase 3 open-label extension study of the pivotal, placebo-controlled REGAIN study of Soliris for the treatment of patients with refractory generalized myasthenia gravis who are anti-acetylcholine receptor antibody-positive. The new results show sustained treatment benefits across a range of MG-specific assessment scales through an additional 52 weeks for patients who continued to receive Soliris, and also demonstrate rapid, significant and sustained improvements through 52 weeks for patients who had crossed over from placebo in REGAIN to Soliris treatment in the extension study. The safety profile of Soliris was consistent with that observed in the REGAIN study. "There is an urgent need for a treatment for patients with refractory gMG who have attempted multiple therapies and continue to suffer from severe symptoms and complications," said Professor James F. Howard, MD, Department of Neurology at the University of North Carolina, Chapel Hill, USA, and lead investigator in REGAIN and its open-label extension study. "These new results build on the findings of the REGAIN study, and it is encouraging to see the rapid and sustained benefits of Soliris treatment with patients recovering functional ability to carry out activities of daily living, and quality of life."

  • 27

    Sep

  • 23

    Oct

ALXN Alexion
$146.46

2.39 (1.66%)

08/16/17
EVER
08/16/17
INITIATION
Target $137
EVER
In Line
Alexion initiated with an In Line at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated Alexion with an In Line and a $137 price target.
09/05/17
JPMS
09/05/17
UPGRADE
Target $175
JPMS
Overweight
Alexion upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Anupam Rama upgraded Alexion Pharmaceuticals to Overweight and raised his price target for the shares to $175 from $163. The stock closed Friday up $1.67 to $144.08. Alexion set low expectations for second half of 2017 earnings and the Street is now shifting its focus to clinical catalysts over the next 6-12 months, Rama tells investors in a research note. The analyst has a positive stance on a supplemental approval of Soliris for myasthenia gravis by the October FDA action date as well as continued confidence in ALXN1210 as a "long-term defense point for Alexion's complement franchise."
09/07/17
LEER
09/07/17
NO CHANGE
LEER
Alexion, Celgene top picks at Leerink
Leerink analyst Geoffrey Porges notes large cap biotech stocks have performed strongly this year and have reversed some of the wide discount they were carrying compared to their history and to other medical products sectors. Further, he points out consensus revenue and earnings estimates for biotech companies have started to trend positively, after negative revisions earlier in the year. Porges still sees significant upside for many of the names in his coverage, and he anticipates that further appreciation can occur on the basis of recovering sentiment and multiples, further estimate revisions toward his current models, and confirmation of option value for unpriced pipeline opportunities. The analyst top picks are now Alexion (ALXN), Celgene (CELG), Regeneron (REGN), and Vertex (VRTX). Among his Market Perform rated stocks, his preference would be for AbbVie (ABBV).
09/13/17
LEER
09/13/17
NO CHANGE
Target $182
LEER
Outperform
Alexion price target raised to $182 from $170 at Leerink
Leerink analyst Geoffrey Porges raised his price target for Alexion to $182 from $170 on valuation. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

SYBX

Synlogic

$18.73

-0.52 (-2.70%)

09:40
09/19/17
09/19
09:40
09/19/17
09:40
Initiation
Synlogic initiated  »

Synlogic initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSU

Kansas City Southern

, KORS

Michael Kors

09:40
09/19/17
09/19
09:40
09/19/17
09:40
Options
Unusually active option classes on open September 19th »

Unusual total active…

KSU

Kansas City Southern

KORS

Michael Kors

AAOI

Applied Optoelectronics

$66.29

7.99 (13.71%)

RAD

Rite Aid

NKE

Nike

M

Macy's

EFX

Equifax

INTC

Intel

VIX

Volatility Index S&P 500 Options

AMD

AMD

$13.08

0.56 (4.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 23

    Sep

  • 25

    Sep

  • 26

    Sep

  • 26

    Sep

  • 28

    Sep

  • 03

    Oct

  • 04

    Oct

  • 05

    Oct

  • 16

    Nov

NKE

Nike

09:37
09/19/17
09/19
09:37
09/19/17
09:37
Recommendations
Nike analyst commentary  »

Nike risk/reward remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 26

    Sep

  • 03

    Oct

  • 04

    Oct

SMBK

SmartFinancial

$23.88

0.38 (1.62%)

09:36
09/19/17
09/19
09:36
09/19/17
09:36
Hot Stocks
SmartFinancial, Capstone Bancshares holders approve merger-related proposals »

SmartFinancial and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:35
09/19/17
09/19
09:35
09/19/17
09:35
General news
FX Action: USD-CAD »

FX Action: USD-CAD edged…

PG

Procter & Gamble

09:34
09/19/17
09/19
09:34
09/19/17
09:34
Hot Stocks
Peltz says Procter & Gamble should have bought Method Soap »

Nelson Peltz of Trian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CORI

Corium

$10.16

0.25 (2.52%)

, NEOS

Neos Therapeutics

$8.70

-0.5 (-5.43%)

09:33
09/19/17
09/19
09:33
09/19/17
09:33
Conference/Events
Mizuho to hold a conference »

Biotechnology CNS Deep…

CORI

Corium

$10.16

0.25 (2.52%)

NEOS

Neos Therapeutics

$8.70

-0.5 (-5.43%)

VYGR

Voyager Therapeutics

$17.36

1.01 (6.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

NVAX

Novavax

$1.12

-0.02 (-1.75%)

09:32
09/19/17
09/19
09:32
09/19/17
09:32
Hot Stocks
Novavax initiates Phase 1/2 trial of NanoFlu vaccine in older adults »

Novavax announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

BSMX

Santander Mexico

09:32
09/19/17
09/19
09:32
09/19/17
09:32
Downgrade
Santander Mexico rating change  »

Santander Mexico…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XPLR

Xplore Technologies

$3.50

-0.2 (-5.41%)

09:31
09/19/17
09/19
09:31
09/19/17
09:31
Hot Stocks
Xplore Technologies secures Android rugged tablet order »

Xplore Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

  • 30

    Nov

SNE

Sony

09:31
09/19/17
09/19
09:31
09/19/17
09:31
Downgrade
Sony rating change  »

Sony downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:30
09/19/17
09/19
09:30
09/19/17
09:30
General news
The U.S. August housing starts report »

The U.S. August housing…

BSX

Boston Scientific

09:29
09/19/17
09/19
09:29
09/19/17
09:29
Hot Stocks
Boston Scientific's HeartLogic Diagnostic shows positive risk detection ability »

Boston Scientific…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBNT

Ubiquiti

$50.62

-4.335 (-7.89%)

09:28
09/19/17
09/19
09:28
09/19/17
09:28
Hot Stocks
Ubiquiti CEO to host Investor Update on September 26 »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

HQY

HealthEquity

$45.77

0.65 (1.44%)

09:26
09/19/17
09/19
09:26
09/19/17
09:26
Conference/Events
HealthEquity participates in a conference call with Chardan »

Conference call with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

UBNT

Ubiquiti

$50.62

-4.335 (-7.89%)

09:26
09/19/17
09/19
09:26
09/19/17
09:26
Hot Stocks
Ubiquiti Board approves additional $100M stock repurchase program »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

UBNT

Ubiquiti

$50.62

-4.335 (-7.89%)

09:23
09/19/17
09/19
09:23
09/19/17
09:23
Earnings
Ubiquiti narrows Q1 revenue view to $240M-$250M, consensus $234.5M »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

LNDC

Landec

$12.80

-0.2 (-1.54%)

09:22
09/19/17
09/19
09:22
09/19/17
09:22
Hot Stocks
Landec provides update on impact from extreme weather events »

Landec provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

BOBE

Bob Evans

$72.93

1.02 (1.42%)

, POST

Post Holdings

09:19
09/19/17
09/19
09:19
09/19/17
09:19
Hot Stocks
On The Fly: Pre-market Movers »

HIGHER: Bob Evans (BOBE),…

BOBE

Bob Evans

$72.93

1.02 (1.42%)

POST

Post Holdings

AZO

AutoZone

TLGT

Teligent

$6.90

-0.29 (-4.03%)

WBA

Walgreens Boots Alliance

$82.60

0.1 (0.12%)

RAD

Rite Aid

APOG

Apogee Enterprises

$44.98

0.18 (0.40%)

EFX

Equifax

ALDX

Aldeyra

$9.10

0.2 (2.25%)

SNCR

Synchronoss

$16.75

0.64 (3.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

  • 19

    Sep

  • 21

    Sep

  • 22

    Sep

  • 27

    Sep

  • 27

    Sep

  • 28

    Sep

  • 30

    Oct

  • 19

    Sep

PG

Procter & Gamble

09:19
09/19/17
09/19
09:19
09/19/17
09:19
Hot Stocks
Peltz says not asking for P&G CEO David Taylor to step down »

Nelson Peltz of Trian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DOX

Amdocs

$64.13

1.64 (2.62%)

09:19
09/19/17
09/19
09:19
09/19/17
09:19
Conference/Events
Amdocs participates in a conference call with Oppenheimer »

Conference call for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TYL

Tyler Technologies

09:18
09/19/17
09/19
09:18
09/19/17
09:18
Hot Stocks
Tyler Technologies selected by Odessa, Texas for ERP solution »

Tyler Technologies signed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

SPX

S&P 500

, VIX

Volatility Index S&P 500 Options

09:18
09/19/17
09/19
09:18
09/19/17
09:18
Options
Overnight activity included 97 trades in SPX and 67 trades in VIX »

97 trades were executed…

SPX

S&P 500

VIX

Volatility Index S&P 500 Options

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APD

Air Products

09:16
09/19/17
09/19
09:16
09/19/17
09:16
Hot Stocks
Air Products awarded oxygen supply contract by South Korean chemical company »

Air Products has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TPIC

TPI Composites

$20.98

-0.05 (-0.24%)

, XYL

Xylem

09:15
09/19/17
09/19
09:15
09/19/17
09:15
Conference/Events
Cowen to hold a summit »

Industrial Innovation…

TPIC

TPI Composites

$20.98

-0.05 (-0.24%)

XYL

Xylem

WLDN

Willdan Group

$29.79

0.71 (2.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

  • 28

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.